Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.58 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.58 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.58 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | PRKX | P51817 | 1/20 | 0.58 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298127 | 0.85 | PARP1 (0.73) | PARP1DHODH | |
| SCHEMBL13544690 | 0.85 | PARP1 (0.73) | PARP1DHODH | |
| SCHEMBL16497016 | 0.81 | PARP1 (0.69) | PARP1PKN1PKN2PLK4MAPK13 | |
| SCHEMBL1933246 | 0.81 | PARP1 (0.69) | PARP1PKN1PKN2PLK4MAPK13 | |
| SCHEMBL6842051 | 0.81 | PARP1 (0.69) | PARP1PKN1PKN2PLK4MAPK13 | |
| SCHEMBL7477535 | 0.81 | PARP1 (0.68) | PARP1PKN1PKN2DHODHPLA2G2A | |
| SCHEMBL23581692 | 0.80 | PARP1 (0.66) | PARP1PKN1PKN2PLK4MAPK13 | |
| SCHEMBL6842030 | 0.80 | PARP1 (0.67) | PARP1PKN1PKN2PLK4MAPK13 | |
| SCHEMBL6842025 | 0.80 | PARP1 (0.66) | PARP1PKN1PKN2PLK4MAPK13 | |
| SCHEMBL16555253 | 0.80 | PARP1 (0.66) | PARP1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841924-B1 | BENZIMIDAZOLE COMPOUNDS | UNIV NEWCASTLE VENTURES LTD (GB) | 2002-10-02 | — | — | EP | claimed |
| US-6310082-B1 | PHARMACEUTICAL COMPOSITION COMPRISING EFFECTIVE POLY(ADP-RIBOSE)POLYMERASE ENZYME INHIBITING AMOUNT OF BENZIMIDAZOLE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT AND/OR PRO-DRUG FORM THEREOF, WITH ACCEPTABLE CARRIER | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-30 | — | — | US | claimed |
| US-6100283-A | PRODRUG PHOSPHATE DERIVATIVE FOR POLY (ADP-RIBOSE) POLYMERASE ENZYME INHIBITOR FOR ADMINISTERING IN CONJUNCTION WITH ANTITUMOR DRUG OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-08-08 | — | — | US | claimed |
| EP-0841924-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-20 | — | — | EP | claimed |
| WO-1997004771-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1997-02-13 | — | — | WO | claimed |
| WO-2023064164-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3471721-B1 | TREATMENT OF VASCULAR CALCIFICATION | CAMBRIDGE ENTPR LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-2389589-B1 | METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS | BRIGHAM & WOMENS HOSPITAL (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140343095-A1 | Methods of Diagnosing and Treating Multiple Sclerosis | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20120077770-A1 | Methods of Diagnosing and Treating Multiple Sclerosis | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| US-7470712-B2 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| EP-0841924-B1 | BENZIMIDAZOLE COMPOUNDS | UNIV NEWCASTLE VENTURES LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| US-6310082-B1 | PHARMACEUTICAL COMPOSITION COMPRISING EFFECTIVE POLY(ADP-RIBOSE)POLYMERASE ENZYME INHIBITING AMOUNT OF BENZIMIDAZOLE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT AND/OR PRO-DRUG FORM THEREOF, WITH ACCEPTABLE CARRIER | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6100283-A | PRODRUG PHOSPHATE DERIVATIVE FOR POLY (ADP-RIBOSE) POLYMERASE ENZYME INHIBITOR FOR ADMINISTERING IN CONJUNCTION WITH ANTITUMOR DRUG OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-08-08 | — | — | US | disclosed |
| EP-0841924-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997004771-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | PARP1 1298/4885PKN1 1221/4885PKN2 1418/4885 |
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PKN1 1633/4885PKN2 1282/4885 |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | P2RY1, P2RY11, P2RY2 | PARP1 459/4885PKN1 802/4885PKN2 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.